How to Get Lunesta (Eszopiclone) in Colorado

What Eszopiclone Is Used For

Eszopiclone is a nonbenzodiazepine hypnotic used to treat insomnia. The current product labeling says it can decrease sleep latency and improve sleep maintenance. The recommended initial adult dose is 1 mg immediately before bedtime, with at least 7 to 8 hours remaining before planned awakening. The dose can be increased when clinically indicated, up to 3 mg 1.

A six-month randomized trial found sustained improvements in sleep measures with nightly eszopiclone compared with placebo in adults with chronic insomnia. The American Academy of Sleep Medicine later issued a weak recommendation for eszopiclone when pharmacologic treatment of adult sleep-onset or sleep-maintenance insomnia is clinically indicated. “Weak” is the guideline's evidence grade, not a statement that the drug never works 2 3.

How to Get a Prescription in Colorado

A practical path is:

1. Choose an in-person or telehealth clinician who is authorized to practice for a patient located in Colorado.
2. Confirm before booking that the clinician evaluates insomnia and, if appropriate, prescribes controlled medications.
3. Provide a sleep history, current medications, substance-use history, medical conditions, prior treatments, and any symptoms suggesting another sleep disorder.
4. If eszopiclone is selected, have the prescription sent to a Colorado pharmacy that has the product in stock and participates in the insurance network.
5. Before pickup, confirm the amount due and whether the plan requires prior authorization or another coverage step.

No clinician or telehealth platform can guarantee a prescription. The decision depends on the evaluation, diagnosis, contraindications, other medicines, and the prescriber's clinical judgment.

Who Can Prescribe Eszopiclone in Colorado

Colorado's Division of Professions and Occupations identifies physicians, physician assistants, and advanced practice nurses with prescriptive authority among the professionals who can prescribe controlled substances within their scope when they hold the required DEA registration. Advanced practice nurses with Colorado RXN authority may prescribe independently within their role and population focus. Colorado physician assistants may prescribe controlled substances under the state's collaborative-agreement framework and must possess a valid DEA registration 6. Colorado PA collaborative-agreement guidance

An out-of-state telehealth registration is not equivalent to a full Colorado credential for this purpose. Colorado's 2024 out-of-state telehealth law specifically prohibits providers practicing only under that registration from prescribing controlled substances. Colorado SB24-141

Can Telehealth Be Used in 2026?

Yes, when the prescriber and encounter satisfy current requirements. HHS and DEA extended the federal telemedicine flexibilities for controlled-medication prescribing through December 31, 2026. Under the extension, a DEA-registered practitioner can prescribe a Schedule II through V controlled substance by telemedicine without a prior in-person medical evaluation if the required conditions are met. The prescription must still be for a legitimate medical purpose and comply with federal and state law 5. HHS telehealth policy summary

The extension is temporary. A patient scheduling after December 31, 2026 should recheck the federal rule because the legal pathway may change. The previous version of this page referred to a 2025 proposal as though it were the operative rule; the current extension is the relevant federal authority.

Colorado generally requires controlled-substance prescriptions to be transmitted electronically, with specified exceptions 7.

What the Evaluation May Include

Insomnia can coexist with sleep apnea, restless legs syndrome, circadian disorders, mood disorders, substance use, medication effects, or medical illness. An evaluation commonly reviews sleep timing and duration, nighttime awakenings, daytime impairment, other medicines and substances, breathing symptoms, and prior behavioral or medication treatment.

A sleep study is not an automatic prerequisite for eszopiclone. AASM diagnostic-testing guidance uses polysomnography or home sleep-apnea testing when obstructive sleep apnea is suspected in an appropriate patient; it does not make testing a universal requirement for every insomnia prescription 9.

The FDA label does not require a routine laboratory panel before treatment. A clinician may order tests when the history suggests another cause or when organ function could affect treatment. Severe hepatic impairment matters because the labeled dose should not exceed 2 mg.

Dosing and Safety Facts That Affect Access

The current label provides these core instructions:

• Start adults at 1 mg immediately before bedtime.
• Take the dose only when at least 7 to 8 hours remain before planned awakening.
• Do not take it with or immediately after a meal.
• Do not exceed 2 mg in older or debilitated adults, people with severe hepatic impairment, or people taking potent CYP3A4 inhibitors.
• Use the lowest effective dose.

Lunesta carries a boxed warning for complex sleep behaviors such as sleep-walking or sleep-driving, which have caused serious injuries and death. The label says to discontinue the drug immediately if a complex sleep behavior occurs. It also warns about next-day impairment, additive effects with alcohol and other central nervous system depressants, abnormal thinking or behavior changes, and the need to evaluate persistent insomnia for another condition 1.

Older adults can be more vulnerable to adverse effects from sedative-hypnotics. A meta-analysis found that improvements in sleep quality in older adults were accompanied by increased adverse events, supporting careful dose selection and reassessment rather than an assumption that a higher dose is better 10.

Colorado Medicaid Coverage

The previous version of this page incorrectly said Health First Colorado did not cover eszopiclone for insomnia. Colorado's January 2026 announcement lists eszopiclone tablets among preferred sedative-hypnotic products. That is materially different from “not covered” 8.

Preferred status does not mean every claim will pay without conditions. Health First Colorado explains that products can still be subject to prior authorization, age, dose, duration, or duplication criteria. Its pharmacy resources page links the current Preferred Drug List and prior-authorization material. Because those files change, check the current version at the time of prescribing. Health First Colorado pharmacy resources

Commercial Insurance and Medicare

Commercial and Medicare coverage varies by plan and effective date. Before the visit, search the plan formulary for both Lunesta and eszopiclone, then inspect the exact strength for:

• formulary tier;
• prior authorization;
• step therapy;
• quantity or duration limits;
• preferred pharmacy requirements; and
• mail-order eligibility.

If a claim is denied, use the rejection message to identify the actual reason. A formulary exception should respond to the plan's stated criteria and document prior treatments, contraindications, adverse effects, or the reason the requested product is necessary. The AASM guideline can support the clinical rationale for eszopiclone, but it does not guarantee insurance coverage.

Filling or Transferring the Prescription

Eszopiclone is available in 1 mg, 2 mg, and 3 mg tablets, but stock can vary by pharmacy and manufacturer. Call the pharmacy before asking the prescriber to transmit the prescription. The pharmacy can also confirm whether it is in network and whether authorization is pending.

Federal Schedule III and IV rules allow up to five refills within six months after the prescription is issued. 21 CFR 1306.22

Federal rules also allow a one-time transfer of an electronic Schedule II through V prescription between retail pharmacies at a patient's request, if state law permits and both pharmacies meet the rule's requirements. Separate rules apply to transferring refill information for Schedule III through V prescriptions. Ask the receiving pharmacy to coordinate the transfer rather than trying to move it yourself. 21 CFR 1306.08 21 CFR 1306.25

Behavioral Treatment Alongside Medication

The AASM strongly recommends multicomponent cognitive behavioral therapy for insomnia (CBT-I) for adults with chronic insomnia. That recommendation and the separate weak recommendation for eszopiclone answer different questions: one addresses behavioral treatment and the other addresses medication when medication is indicated. A clinician and patient can decide whether to use CBT-I, medication, or both based on symptoms, access, prior response, and risk 4 3.

The prior page incorrectly described a benzodiazepine-discontinuation trial as a study of eszopiclone plus CBT-I. That study did not test eszopiclone and is not evidence for that claim.